Cellceutix Completes Final Study to File IND Application for New Psoriasis Drug Prurisol(TM)

Cellceutix Completes Final Study to File IND Application for New Psoriasis Drug 
Prurisol(TM) 
BEVERLY, MA -- (Marketwired) -- 10/02/13 --  Cellceutix Corporation
(OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical
company focused on discovering, developing and commercializing drugs
to treat unmet medical conditions, today announces that the bridging
study on Prurisol, the Company's anti-psoriasis drug candidate, has
been completed by an outside vendor and that Cellceutix has received
the report. The study documents the ester bond in Prurisol(TM) (a
prodrug) is readily cleaved and converted as expected. This study was
requested by the Food and Drug Administration to be included in the
Investigational New Drug ("IND") application with the FDA under a
505(b)(2) designation. This completes the lab studies needed for
filing an IND for Prurisol. 
Cellceutix is reviewing clinical sites in the United States and
internationally to initiate a Phase 2/3 trial as Dr. Reddy's
Laboratories Ltd. finalizes the Chemistry, Manufacturing, and
Controls section ("CMC") of the IND. The CMC is expected by the end
of the month and the IND filing shortly thereafter. Dr. Reddy's has
already completed the manufacturing and stability studies of Prurisol
for a multi-center clinical trial. 
"I wish to thank Dr. Reddy's Laboratories for their assistance in
this study. The results from the final study for the FDA submission
were exactly as expected. We are very eager to move Prurisol into a
large-scale human trial, where we are optimistic that the drug will
validate earlier research and prove itself as a new, potent
therapeutic for psoriasis," commented Dr. Krishna Menon, Chief
Scientific Officer of Cellceutix. "Meanwhile, we are moving quickly
with the regulatory work with our new antibiotic, Brilacidin(TM), to
begin a Phase 2b clinical trial for ABSSSI and phase 2 trial for oral
mucositis. In recent weeks, we have added to our clinical support
staff in preparation for all of the trials in addition to the ongoing
Phase 1 trial of our anti-cancer drug Kevetrin(TM). We have been
advised that the Safety Review Committee is meeting early next week
to determine the dosing levels of Kevetrin for the sixth cohort in
the trial at Dana-Farber Cancer Institute and Beth Israel Deaconess
Medical Center. We anticipate that the dosing will be above 100
mg/m2, a level that we have considered an important dose since the
trial began. This is an exciting time as there are many, many
positive developments happening concurrently as we align to conduct
multiple clinical trials with our extremely promising compounds." 
About Cellceutix 
Headquartered in Beverly, Massachusetts, Cellceutix is a publicly
traded company under the symbol "CTIX". Cellceutix is a clinical
stage biopharmaceutical company focused on developing and
commercializing its pipeline of compounds for novel therapies in
areas of serious unmet medical need, including cancer, psoriasis and
antibiotic applications. More information is available on the
Cellceutix web site at www.cellceutix.com. 
Safe Harbor Forward-Looking Statements 
To the extent that statements in this press release are not strictly
historical, including statements as to revenue projections, business
strategy, outlook, objectives, future milestones, plans, intentions,
goals, future financial conditions, future collaboration agreements,
the success of the Company's development, events conditioned on
stockholder or other approval, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995. The forward-looking statements contained in this release are
subject to certain risks and uncertainties that could cause actual
results to differ materially from the statements made. Factors that
may impact Cellceutix's success are more fully disclosed in
Cellceutix's most recent public filings with the U.S. Securities and
Exchange Commission. 
Cellceutix Corp.
Leo Ehrlich
(978) 236-8717
info@cellceutix.com